Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

451
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
451
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

1.7K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.7K
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

3.0K
Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
3.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

368
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
368
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

1.6K
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
1.6K
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

5.7K
Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
5.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Promoting clinical trials in pediatric IgA nephropathy through extrapolation: an artificial intelligence-enhanced literature review of the disease in pediatrics sponsored by the Kidney Health Initiative.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.

Kidney international reports·2025
Same author

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

The New England journal of medicine·2025
Same author

Association of Plasma Uremic Solute Levels with Residual Kidney Function in Children on Peritoneal Dialysis.

Clinical journal of the American Society of Nephrology : CJASN·2021
Same author

Establishing core outcome domains in pediatric kidney disease: report of the Standardized Outcomes in Nephrology-Children and Adolescents (SONG-KIDS) consensus workshops.

Kidney international·2020
Same author

Cortical and trabecular bone are equally affected in rats with renal failure and secondary hyperparathyroidism.

BMC nephrology·2018

Related Experiment Video

Updated: Mar 21, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.3K

Inpatient citrate-based hemodialysis in pediatric patients.

Cecile Fajardo1, Cheryl P Sanchez1, Drew Cutler1

  • 1Department of Pediatrics, Loma Linda University Children's Hospital, Loma Linda, CA, 92354, USA.

Pediatric Nephrology (Berlin, Germany)
|May 12, 2016
PubMed
Summary

Citrate-based dialysate offers a safe alternative for pediatric hemodialysis (HD) anticoagulation, showing low rates of thrombosis and mild hypocalcemia. This method is well-tolerated in hospitalized children requiring HD.

Keywords:
AnticoagulationCitrateDialysis complicationsHemodialysisPediatric dialysis

More Related Videos

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.5K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

16.2K

Related Experiment Videos

Last Updated: Mar 21, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
06:27

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice

Published on: July 20, 2022

3.3K
Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model
04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

1.5K
Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
07:11

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis

Published on: July 19, 2018

16.2K

Area of Science:

  • Pediatric Nephrology
  • Renal Replacement Therapy
  • Clinical Pharmacology

Background:

  • Citrate-based dialysate is an established hemodialysis (HD) anticoagulation method for adults.
  • Heparin anticoagulation is commonly used in pediatric HD but carries risks.
  • Evaluating citrate dialysate as a safer alternative in pediatric patients is crucial.

Purpose of the Study:

  • To assess the efficacy and safety of citrate-based dialysate for anticoagulation in pediatric hemodialysis.
  • To compare citrate dialysate with heparin anticoagulation in terms of thrombosis and complications.
  • To determine the feasibility of using citrate dialysate in hospitalized pediatric patients.

Main Methods:

  • A prospective, non-randomized study involving 18 pediatric patients (0-18 years) undergoing 119 citrate-based dialysate HD treatments.
  • Primary outcomes included thrombosis incidence leading to circuit or catheter loss, or dialysis termination.
  • Secondary outcomes measured were hypocalcemia and the need for additional heparin.

Main Results:

  • Low rates of thrombosis-related circuit loss (2.5%), catheter loss (2.5%), and early dialysis termination (5.9%) were observed.
  • Circuit clots occurred in 64% of treatments without loss; mild, asymptomatic hypocalcemia developed in 58% of sessions.
  • No additional heparin was required during citrate HD, though 11.1% were later switched to heparin.

Conclusions:

  • Citrate-based dialysate demonstrated a low incidence of severe thrombotic events in pediatric hemodialysis.
  • While hypocalcemia was frequent, it was mild and asymptomatic, indicating good tolerability.
  • Citrate-based dialysate is a safe and effective alternative to heparin for anticoagulation in pediatric HD patients.